TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01489046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986001
Description: Capsules, Oral, 100 mg, Once daily, At least 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986001
Description: Capsules, Oral, 200 mg, Once daily, At least 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986001
Description: Capsules, Oral, 400 mg, Once daily, At least 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986001
Description: Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Study: NCT01749878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500
Study: NCT01489046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986001
Description: Capsules, Oral, 0 mg, Once daily, At least 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Study: NCT03330275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A
Study: NCT01749878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03330275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles
Study: NCT01749878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04239976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MC5-A Scrambler Therapy
Description: Undergo scrambler therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Undergo quantitative sensory test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02473549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TDCS
Description: Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal TDCS
Description: Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
Study: NCT03330275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles
Study: NCT00665327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
Study: NCT02962440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
Study: NCT02660489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02473549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
Study: NCT00956527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified traditional martial arts training
Description: Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts.
Study: NCT02641431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mapping/ablation
Description: Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ajmaline
Description: Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mapping
Description: A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
Study: NCT03896321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: effect of dual antiplatelet in management of coronary artery ectasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: effect of dual antiplatelet in management of coronary artery ectasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: effect of oral anticoagulants in management of coronary artery ectasia
Study: NCT02660489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Description: Inoculation with rhinovirus serotype 16
Study: NCT03896321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: effect of oral anticoagulants in management of coronary artery ectasia
Study: NCT01012258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab + concomitant boost radiotherapy
Description: Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval
Study: NCT02952599

Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study: NCT03600740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Programming
Description: DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
Study: NCT01450865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flupirtine
Description: Potassium channel opener (SNEPCO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flupirtine
Description: Potassium channel opener (SNEPCO)
Study: NCT02890602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
Study: NCT04412616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.
Study: NCT01854970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
Study: NCT02445872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
Study: NCT04412616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZZ06
Description: The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg.
Study: NCT02029118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)
Description: Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Study: NCT03955341

Intervention type: DEVICE
Group type: OTHER
Intervention: Diode laser disinfection
Description: After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
Study: NCT02029118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)
Description: Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint
Description: select acupoint according to traditional Chinese medicine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: acupoint
Description: select acupoint according to traditional Chinese medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Description: foundation treatment
Study: NCT00567008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 1.0 mg BID for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BID for 8 weeks
Study: NCT02445872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03955341

Intervention type: OTHER
Group type: OTHER
Intervention: Chemical disinfection using 2% Chlorhexidine
Description: After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
Study: NCT02660489

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rhinovirus
Description: Inoculation with rhinovirus serotype 16
Study: NCT02841332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-MISO
Description: The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral magnetic resonance imagery
Description: During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment
Study: NCT03028077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GS-3K8
Description: GS-3K8 (ultrafiltered red ginseng extract) 1 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GINst15
Description: GINst15 (hydrolyzed ginseng extract) 1 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 g/day
Study: NCT00103389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: PI-88+docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel only
Study: NCT03673111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y14
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y14
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y14
Description: Gut hormone analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y14
Description: Gut hormone analogue
Study: NCT02445872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT01933490

Intervention type: OTHER
Group type: OTHER
Intervention: high carbohydrate test meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high carbohydrate test meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high carbohydrate test meal

Intervention type: OTHER
Group type: OTHER
Intervention: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high carbohydrate test meal after pre-treatment with rapid acting aspart insulin

Intervention type: OTHER
Group type: OTHER
Intervention: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Study: NCT01489046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Study: NCT01489046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Study: NCT01586468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WF10
Description: 0.5 mg/kg B.W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl Solution
Description: NaCl Solution
Study: NCT03673111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y14
Description: Gut hormone analogue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT03620669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg q4W until progression or unacceptable toxicity
Study: NCT03361709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solutions, Intraocular
Description: Only saline will be injected intracamerally at conclusion of Phacoemulsification